Results 311 to 320 of about 1,543,966 (410)

Why and how do we perform physical examination(s) in clinical trials? A use case of drug intervention trials in type 2 diabetes mellitus

British Journal of Clinical Pharmacology, EarlyView.
Aims The aim of this study was to determine the purpose and use of physical examination (PE) in phase 3 and 4 drug interventional clinical trials within type 2 diabetes mellitus. Methods A total of 226 clinical trial protocols identified from the ClinicalTrials.gov database were systematically reviewed by five researchers.
Julia Kopanz, Amy Rogers, Lina Pérez‐Breva, Emily Hall, Prashasthi Devaiah, Isla S. Mackenzie, Bart Lagerwaard, Diederick E. Grobbee, Mira G. P. Zuidgeest, on behalf of the Trials@Home consortium   +9 more
wiley   +1 more source

Endogenous Levels, Detection Time, and Symptoms of Gamma-Hydroxybutyric Acid: Results From a Placebo-Controlled Clinical Trial. [PDF]

Basic Clin Pharmacol Toxicol
Faldborg KB, Sørensen LK, Hasselstrøm JB, Andersen CU.   +3 more
europepmc   +1 more source

Role of Anticholinergic, Uroselective α 1D/1A Blocker, Combination of Two Drugs and Placebo in Treatment of Ureteral Stent Related Discomfort and Urinary Symptoms

, 2019
Syed Jamal Rizvi, Ujwal Kumar, Jyoti Bansal, Niroj Bhandari   +3 more
openalex   +1 more source

Interleukin (IL)‐5, Eosinophils and IL‐5 Pathway Inhibitors in Eosinophilic Granulomatosis with Polyangiitis.

Arthritis &Rheumatology, Accepted Article.
Alvise Berti, Christian Pagnoux
wiley   +1 more source

AZD0449, an inhaled JAK1 inhibitor, in healthy participants and patients with mild asthma

British Journal of Clinical Pharmacology, EarlyView.
Aims Inhaled corticosteroids (ICS) plus bronchodilator are recommended for the treatment of asthma. Targeting the JAK1‐dependent pathway may be an alternative for asthma management in patients with incomplete response to ICS. The aim of this study was to investigate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD0449, a
Anna Lundahl, Rod Hughes, Joachim Almquist, David Close, Jukka Mäenpää, Ulrika Tehler, Tina Jellesmark Jensen, Szilárd Nemes, Anne‐Kristina Mercier, Zala Jevnikar, Pablo Forte Soto, Dave Singh   +11 more
wiley   +1 more source

Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Comparison of the Analgesic Efficacy and Safety of Intravenous Ketoprofen, Tramadol, and Morphine After Bony Impacted Mandibular Third Molar Surgery. [PDF]

Cureus
Babul A, Gill A, Ashraf S, Hussain M, Babul N.   +4 more
europepmc   +1 more source

The effects of pramipexole on motivational vigour during a saccade task: a placebo-controlled study in healthy adults

Sheena K. Au‐Yeung, Don Chamith Halahakoon, Alexander Kaltenboeck, Philip J. Cowen, Michael Browning, Sanjay Manohar   +5 more
openalex   +1 more source

Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience

British Journal of Clinical Pharmacology, EarlyView.
Problem setting The emergence of therapeutic proteins has coincided with an increase of acute adverse immunostimulation (AIS). AIS has occured in clinical trials despite compliance with regulatory guidelines on preclinical evaluation and its incidence is anticipated to increase even further.
Juliette A. van den Noort, Marella C. E. van Ruissen, Lisanne C. A. Smidt, Naomi B. Klarenbeek, Philip H. K. Kremer, Manon A. A. Jansen, Jacobus Burggraaf, Joop M. A. van Gerven, Matthijs Moerland   +8 more
wiley   +1 more source

Pirfenidone treatment improves ischemic muscle function in mice with chronic kidney disease. [PDF]

Skelet Muscle
Balestrieri N, Dong G, Ryan TE.
europepmc   +1 more source

Ileal bile acid transporter inhibitors in Alagille syndrome and Progressive Familial Intrahepatic Cholestasis: A systematic review into dose–response

British Journal of Clinical Pharmacology, EarlyView.
Ileal bile acid transporter inhibitors (IBATi), including maralixibat and odevixibat, are a novel approach to the treatment of paediatric cholestatic liver diseases, such as Alagille syndrome (ALGS) and different forms of progressive familial intrahepatic cholestasis (PFIC).
Alise D. E. de Groot, Cristina Chiadò, Jos G. W. Kosterink, Willem S. Lexmond, Paola Mian, Henkjan J. Verkade   +5 more
wiley   +1 more source